Results 21 to 30 of about 38,942 (318)
Canadian Medical Association Journal, 2011 Ranibizumab is a recombinant, monoclonal antibody fragment that inhibits vascular endothelial growth factor (known as a VEGF-A inhibitor).1 Because it costs about 10 times more than bevacizumab,2 an anti-VEGF agent approved for intravenous use in metastatic colon cancer, ophthalmologists may ...
Jason Noble, Varun Chaudhary
openaire +2 more sources
Effect of ranibizumab on retinopathy of prematurity: A meta-analysis
Frontiers in Pharmacology, 2022 The primary objective of this study was to systematically evaluate the clinical efficacy of intravitreal ranibizumab injection in the treatment for retinopathy of prematurity (ROP) in infants.
Zhibin Wang +3 more
semanticscholar +1 more source
Mass spectrometry in ocular drug research
Mass Spectrometry Reviews, EarlyView., 2023 Abstract Mass spectrometry (MS) has been proven as an excellent tool in ocular drug research allowing analyzes from small samples and low concentrations. This review begins with a short introduction to eye physiology and ocular pharmacokinetics and the relevance of advancing ophthalmic treatments.
Eva M. del Amo +6 more
wiley +1 more source
JAMA ophthalmology, 2022 This post hoc analysis of an equivalence trial investigates the association of immunogenicity to ranibizumab products with efficacy, safety, and pharmacokinetics in patients with neovascular age-related macular degeneration.
N. Bressler +5 more
semanticscholar +1 more source
PLoS ONE, 2022 Purpose This study aimed to establish the efficacy, safety, and immunogenicity equivalence of the proposed biosimilar CKD-701 with the reference ranibizumab in patients with treatment-naïve neovascular age-related macular degeneration (nAMD).
C. Yoon +5 more
semanticscholar +1 more source
Indian Journal of Ophthalmology, 2022 Purpose: The present study compares the efficacy, safety, and immunogenicity of Lupin’s biosimilar ranibizumab with that of Lucentis® in patients with neovascular age-related macular degeneration.
Ramandeep Singh +10 more
semanticscholar +1 more source
Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. [PDF]
PLoS ONE, 2014 Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the
Paul Mitchell +9 more
doaj +1 more source
Ophthalmology and Therapy, 2022 Ladder was a phase 2 trial that evaluated the Port Delivery System with ranibizumab (PDS) for neovascular age-related macular degeneration. Serum and aqueous humor samples were collected to characterize the pharmacokinetics (PK) of ranibizumab delivered ...
C. Wykoff +8 more
semanticscholar +1 more source
Cost effectiveness of treatments for wet age-related macular degeneration [PDF]
, 2011 Age-related macular degeneration (AMD) is a leading cause of blindness in people aged >= 50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems.
Annemans, Lieven +4 more
core +1 more source
Protective effects on the retina after ranibizumab treatment in an ischemia model. [PDF]
PLoS ONE, 2017 Retinal ischemia is common in eye disorders, like diabetic retinopathy or retinal vascular occlusion. The goal of this study was to evaluate the potential protective effects of an intravitreally injected vascular endothelial growth factor (VEGF ...
Stephanie C Joachim +10 more
doaj +1 more source